See more : Phibro Animal Health Corporation (PAHC) Income Statement Analysis – Financial Results
Complete financial analysis of Kura Oncology, Inc. (KURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kura Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bangkok Commercial Property Fund (BKKCP.BK) Income Statement Analysis – Financial Results
- VLS Finance Limited (VLSFINANCE.NS) Income Statement Analysis – Financial Results
- Apacer Technology Inc. (8271.TW) Income Statement Analysis – Financial Results
- GMR Airports Infrastructure Limited (GMRINFRA.BO) Income Statement Analysis – Financial Results
- Cognition Therapeutics, Inc. (CGTX) Income Statement Analysis – Financial Results
Kura Oncology, Inc. (KURA)
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 849.00K | 759.00K | 558.00K | 194.00K | 0.00 | 10.00K | 30.00K | 31.00K | 20.00K | 23.91K | 22.73K | 22.34K | 23.44K | 20.51K | 19.16K | 0.00 |
| Gross Profit | -849.00K | -759.00K | -558.00K | -194.00K | 0.00 | -10.00K | -30.00K | -31.00K | -20.00K | -23.91K | -22.73K | -22.34K | -23.44K | -20.51K | -19.16K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 115.24M | 92.81M | 84.72M | 60.40M | 47.83M | 46.79M | 26.43M | 20.40M | 17.78M | 8.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 50.57M | 47.05M | 46.54M | 31.50M | 19.65M | 16.10M | 9.65M | 7.96M | 6.09M | 3.85M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.57M | 47.05M | 46.54M | 31.50M | 19.65M | 16.10M | 9.65M | 7.96M | 6.09M | 3.85M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | 0.00 |
| Other Expenses | 0.00 | 4.03M | 792.00K | 2.27M | 4.34M | 2.44M | 643.00K | 807.00K | 1.24M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.62K |
| Operating Expenses | 165.80M | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M | 36.08M | 28.37M | 23.87M | 10.90M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | -33.62K |
| Cost & Expenses | 165.80M | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M | 36.08M | 28.37M | 23.87M | 10.90M | 22.34K | 23.44K | 20.51K | 41.02K | 38.32K | -33.62K |
| Interest Income | 14.72M | 4.25M | 1.21M | 2.80M | 4.67M | 3.17M | 751.00K | 499.00K | 128.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.55M | 229.00K | 414.00K | 578.00K | 580.00K | 970.00K | 888.00K | 577.00K | 88.00K | 5.88K | 4.97K | 3.60K | 1.89K | 1.89K | 838.00 | 0.00 |
| Depreciation & Amortization | 849.00K | 759.00K | 558.00K | 194.00K | 10.00K | 10.00K | 30.00K | 31.00K | 20.00K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -164.96M | -139.11M | -129.71M | -91.71M | -67.48M | -62.87M | -36.05M | -28.34M | -23.85M | -11.80M | -22.34K | -23.44K | -20.51K | -41.02K | -38.32K | -33.62K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -165.80M | -140.62M | -131.82M | -92.09M | -67.48M | -62.88M | -36.08M | -28.37M | -23.87M | -11.80M | -22.34K | -23.44K | -20.51K | -41.02K | -38.32K | -33.62K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.17M | 4.03M | 792.00K | 2.27M | 4.44M | 2.64M | 943.00K | 807.00K | 972.00K | 879.00K | 16.86K | 17.37K | 19.84K | 18.62K | 18.32K | 0.00 |
| Income Before Tax | -152.63M | -135.84M | -130.47M | -89.63M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.40K | -22.40K | -20.00K | -33.62K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 229.00K | -558.00K | -194.00K | -10.00 | 3.41M | -30.00K | -31.00K | -20.00K | 268.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -152.63M | -136.07M | -129.91M | -89.43M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.40K | -22.40K | -20.00K | -33.62K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.08 | -2.03 | -1.96 | -1.68 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -78.11 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.08 | -2.03 | -1.96 | -1.68 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -78.11 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.70M | 9.93M | 141.00K | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M | 0.00 |
| Weighted Avg Shares Out (Dil) | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.70M | 9.93M | 141.00K | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M | 0.00 |
Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC
– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR – – Data validate activity of farnesyltransferase inhibitors and support rapid advancement of KO-2806 into combinations with targeted therapies in large solid tumor indications – – Results to...
What Makes Kura Oncology (KURA) a New Buy Stock
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12 D inhibitors –
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer
– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors –
Kura's Ziftomenib: The Swiss Army Knife In AML Therapy
Kura Oncology's lead candidate, ziftomenib, shows dual-functionality in treating NPM1-mutant AML and overcoming resistance mutations. Company's financials robust with $477M in liquid assets, offsetting a manageable monthly cash burn of $10.2M, providing a 46.8-month cash runway. Given the clinical promise...
Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming Cantor Global Healthcare...
Life Science Cares Announces Impact Level Partnership with Kura Oncology
CAMBRIDGE, Mass. & SAN DIEGO--(BUSINESS WIRE)--Life Science Cares (LSC) is thrilled to announce a new $250,000 partnership with Kura Oncology to provide additional grant funding for educational initiatives in both San Diego and Greater Boston. The partnership will ensure funding...
Kura Oncology Appoints Brian Powl as Chief Commercial Officer
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial...
Kura Oncology, Inc. (KURA) Q2 2023 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President, Investor Relations & Corporate Communications Troy Wilson - President & Chief Executive Officer Tom Doyle...
Kura Oncology Reports Second Quarter 2023 Financial Results
– Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented...
Source: https://incomestatements.info
Category: Stock Reports